Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia

Constantine E Kosmas,1,2 Maria D Bousvarou,3 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,2 Rogers Echavarria Uceta,2 Eliscer Guzman1,2 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2Cardiology Clinic, Cardiology Unlimited, PC, N...

Full description

Bibliographic Details
Main Authors: Kosmas CE, Bousvarou MD, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E
Format: Article
Language:English
Published: Dove Medical Press 2022-07-01
Series:Clinical Pharmacology: Advances and Applications
Subjects:
cardiovascular disease
angptl3 inhibitors
evinacumab
refractory hypercholesterolemia
familial hypercholesterolemia
ldl-cholesterol
ldl receptors
antisense oligonucleotides
vupanorsen.
Online Access:https://www.dovepress.com/angiopoietin-like-protein-3-angptl3-inhibitors-in-the-management-of-re-peer-reviewed-fulltext-article-CPAA

Internet

https://www.dovepress.com/angiopoietin-like-protein-3-angptl3-inhibitors-in-the-management-of-re-peer-reviewed-fulltext-article-CPAA

Similar Items